Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
AAA, accelerated, adenocarcinoma, aldoxorubicin, APA, ApS, arimoclomol, assigned, Assignment, calendar, Carlo, colorectal, consecutive, Denmark, ductal, estimatable, exceeded, fourth, hurdle, ImmunityBio, KemPharm, LadRx, metastatic, Monte, NantCell, orphan, Orphazyme, pancreatic, pool, PSU, sooner, title, tranche, Zevra
Removed:
penalty, spread
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view